Physician profile
John Scott Erwin
NPI 1518906858
$12,415.12
in general payments reported to CMS, 2019-2025
58 companies · $1,666 in 2025
The $1,666 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,564 · 2020: $1,639 · 2021: $2,123 · 2022: $2,008 · 2023: $1,957 · 2024: $1,458 · 2025: $1,666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,080.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,734.01 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,087.24 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Otsuka America Pharmaceutical, INC. | $940.21 | 2019-2025 | Rexulti, Abilify Maintena |
| Pfizer INC. | $869.46 | 2019-2025 | |
| Horizon Therapeutics Plc | $825.48 | 2019-2022 | |
| Glaxosmithkline, LLC. | $694.25 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $538.27 | 2019-2025 | Repatha, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $530.45 | 2019-2025 | Spravato |
| Antares Pharma, INC. | $518.24 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Abbott Laboratories | $401.70 | 2020-2025 | Freestyle Libre 3, Cardiomems |
| Astellas Pharma US INC | $377.86 | 2019-2024 | Veozah |
| Genentech USA, INC. | $285.63 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $256.68 | 2019-2022 | |
| Novo Nordisk INC | $249.71 | 2019-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $249.05 | 2019-2021 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Erwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.